Febuxostat capsules and their preparation method

By preparing febuxostat capsules and utilizing components such as Dendrobium extract and Spirulina extract, the problem of the slow onset of febuxostat's efficacy was solved, achieving stability and uniformity of the active pharmaceutical ingredients, thereby improving efficacy and clinical application results.

CN116570573BActive Publication Date: 2026-11-17HAINAN LINHENG PHARMA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310493030.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-30
Publication Date
2026-11-17
Estimated Expiration
2043-04-30

AI Technical Summary

Technical Problem

Existing febuxostat formulations suffer from limited solubility, making it difficult for the drug to exert its effects quickly. Furthermore, the existing tablet form is not conducive to the full realization of the drug's efficacy.

Method used

Using febuxostat capsules, a uniform and stable capsule filler was prepared by adding Dendrobium extract and Spirulina extract, combined with micronized silica gel, alginic acid, mannitol, citric acid and pregelatinized starch, and then filling the empty capsules.

Benefits of technology

It improves the stability and uniformity of the active pharmaceutical ingredients, ensures rapid efficacy, and significantly enhances the effectiveness of clinical applications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical preparations, specifically relating to a febuxostat capsule and its preparation method. The invention includes an empty capsule and a filler filling the empty capsule; the filler comprises the following components in parts by weight: 10-50 parts febuxostat, 10-20 parts Dendrobium officinale extract, 20-30 parts Spirulina extract, 5-15 parts micronized silica gel, 0.1-1 parts alginic acid, 1-5 parts mannitol, 5-20 parts citric acid, 30-80 parts pregelatinized starch, and 0.5-3 parts magnesium stearate. The filler of this invention, by adding Dendrobium officinale extract and Spirulina extract, can effectively improve the stability of the filler, which is beneficial for maintaining stable drug activity. Febuxostat capsules prepared using the febuxostat capsule filler of this invention have good content uniformity and good stability, which is beneficial for improving efficacy and greatly facilitating clinical application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical preparations, specifically relating to a febuxostat capsule and its preparation method. Background Technology

[0002] Gout is a chronic disease caused by a disorder of purine metabolism, increased uric acid synthesis and / or decreased uric acid excretion, resulting from the combined effects of genetic and environmental factors. It is mainly characterized by hyperuricemia, recurrent acute gouty arthritis attacks, tophi deposition, chronic gouty arthritis and joint deformities, renal parenchymal lesions, and uric acid stone formation.

[0003] Febuxostat is a commonly used anti-gout drug that, when taken orally, combats hyperuricemia. Its uric acid-lowering efficacy is superior to allopurinol, with fewer adverse reactions, making it widely used among patients with hyperuricemia and gout. Currently, febuxostat formulations are primarily in tablet form. However, due to the limited solubility of febuxostat itself, and the need for disintegration after tablet preparation, the efficacy of febuxostat is not optimal. Capsules, on the other hand, do not require tablet compression and can exert their effect more quickly after oral administration. Therefore, developing febuxostat capsules with uniform quality and stable efficacy is of positive significance for the clinical application of febuxostat. Summary of the Invention

[0004] This invention provides a febuxostat capsule and its preparation method, which has uniform quality and the content of active ingredients can remain stable for a long time, which is conducive to the efficacy of the drug.

[0005] The technical solution of this invention is implemented as follows:

[0006] A febuxostat capsule filler comprises the following components in parts by weight: 10-50 parts febuxostat, 10-20 parts Dendrobium officinale extract, 20-30 parts Spirulina extract, 5-15 parts micronized silica gel, 0.1-1 part alginic acid, 1-5 parts mannitol, 5-20 parts citric acid, 30-80 parts pregelatinized starch, and 0.5-3 parts magnesium stearate.

[0007] Furthermore, the febuxostat capsule filler comprises the following components in parts by weight: 30 parts febuxostat, 15 parts Dendrobium extract, 25 parts Spirulina extract, 10 parts micronized silica, 0.5 parts alginic acid, 3 parts mannitol, 15 parts citric acid, 50 parts pregelatinized starch, and 2.5 parts magnesium stearate.

[0008] Furthermore, the preparation method of the aforementioned febuxostat capsule filler and Dendrobium extract is as follows:

[0009] Take dried whole Dendrobium officinale, cut it into small sections, add 10-20 times the weight of the herb to deionized water, soak and extract three times at 80-90℃ for 2 hours each time. After the extract is concentrated, add anhydrous ethanol, centrifuge to separate the precipitate, add deionized water to dissolve it, centrifuge again, and freeze-dry the supernatant under vacuum to obtain Dendrobium officinale extract.

[0010] Furthermore, the preparation method of the febuxostat capsule filler and spirulina extract is as follows:

[0011] Take spirulina powder, pulverize it into ultrafine powder, add 3-4 times the weight of water to spirulina, heat to 80-100℃ for 8-10 hours, centrifuge to remove the precipitate, add an equal volume of anhydrous ethanol to the supernatant, stir thoroughly, and centrifuge; take the precipitate, dissolve it in water, add 1 / 2 volume of anhydrous ethanol to the aqueous solution, stir thoroughly, centrifuge, and dry the resulting precipitate to obtain spirulina extract.

[0012] Furthermore, the centrifugation speed is controlled at 5000-8000 rpm for 15 minutes.

[0013] The above-mentioned febuxostat capsule filler is used in the preparation of febuxostat capsules.

[0014] A febuxostat capsule includes an empty capsule and a filler filling the empty capsule; the filler is the febuxostat capsule filler described above.

[0015] A method for preparing febuxostat capsules includes the following steps:

[0016] (1) Take Dendrobium polysaccharide and Spirulina extract separately and pulverize them into ultrafine powder; pulverize alginic acid, mannitol, citric acid and pregelatinized starch through a 60-80 mesh sieve; mix them evenly with the pulverized Spirulina extract, add water to make soft powder, granulate and dry;

[0017] (2) After drying, add micronized silica gel and magnesium stearate to the granules, mix evenly, and then fill into empty capsules.

[0018] Furthermore, both the Dendrobium extract and the Spirulina extract are pulverized to a particle size of less than or equal to 30 μm.

[0019] Furthermore, in step (2), the particles are dried until the moisture content is less than 2%.

[0020] Beneficial effects:

[0021] The febuxostat capsule filler of this invention, by adding Dendrobium officinale extract and Spirulina extract, can effectively improve the stability of the filler and help maintain stable drug activity. Febuxostat capsules prepared using the febuxostat capsule filler of this invention have good content uniformity and good stability, which is beneficial to improving efficacy and greatly facilitating clinical application. Detailed Implementation

[0022] The present invention will be further described below with reference to specific embodiments in order to better understand the present invention.

[0023] Example 1

[0024] A febuxostat capsule filler comprises the following components in parts by weight: 10 parts febuxostat, 10 parts Dendrobium extract, 20 parts Spirulina extract, 5 parts micronized silica, 0.1 parts alginic acid, 1 part mannitol, 5 parts citric acid, 30 parts pregelatinized starch, and 0.5 parts magnesium stearate.

[0025] The above-mentioned febuxostat capsule filler can be used directly to prepare febuxostat capsules.

[0026] A febuxostat capsule includes an empty capsule and a filler filling the empty capsule; the filler is the febuxostat capsule filler described above.

[0027] The method for preparing the aforementioned febuxostat capsules includes the following steps:

[0028] (1) Take Dendrobium polysaccharide and Spirulina extract separately, and pulverize them into ultrafine powder with a particle size of less than or equal to 30 μm; pulverize alginic acid, mannitol, citric acid and pregelatinized starch through a 60-mesh sieve; mix them evenly with the pulverized Spirulina extract, add water to make soft powder, granulate, and dry to a moisture content of less than 2%;

[0029] (2) After drying, add micronized silica gel and magnesium stearate to the granules, mix evenly, and then fill into empty capsules.

[0030] Example 2

[0031] A febuxostat capsule filler comprises the following components in parts by weight: 30 parts febuxostat, 15 parts Dendrobium extract, 25 parts Spirulina extract, 10 parts micronized silica, 0.5 parts alginic acid, 3 parts mannitol, 15 parts citric acid, 50 parts pregelatinized starch, and 2.5 parts magnesium stearate.

[0032] The above-mentioned febuxostat capsule filler can be used directly to prepare febuxostat capsules.

[0033] A febuxostat capsule includes an empty capsule and a filler filling the empty capsule; the filler is the febuxostat capsule filler described above.

[0034] The method for preparing the aforementioned febuxostat capsules includes the following steps:

[0035] (1) Take Dendrobium polysaccharide and Spirulina extract separately, and pulverize them into particles with a particle size of less than or equal to 30 μm; pulverize alginic acid, mannitol, citric acid and pregelatinized starch through a 70-mesh sieve; mix them evenly with the pulverized Spirulina extract, add water to make soft powder, granulate, and dry to a moisture content of less than 2%;

[0036] (2) After drying, add micronized silica gel and magnesium stearate to the granules, mix evenly, and then fill into empty capsules.

[0037] Example 3

[0038] A febuxostat capsule filler comprises the following components in parts by weight: 50 parts febuxostat, 20 parts Dendrobium extract, 30 parts Spirulina extract, 15 parts micronized silica, 1 part alginic acid, 5 parts mannitol, 20 parts citric acid, 80 parts pregelatinized starch, and 3 parts magnesium stearate.

[0039] The above-mentioned febuxostat capsule filler can be used directly to prepare febuxostat capsules.

[0040] A febuxostat capsule includes an empty capsule and a filler filling the empty capsule; the filler is the febuxostat capsule filler described above.

[0041] The method for preparing the aforementioned febuxostat capsules includes the following steps:

[0042] (1) Take Dendrobium polysaccharide and Spirulina extract separately, and pulverize them into particles with a particle size of less than or equal to 30 μm; pulverize alginic acid, mannitol, citric acid and pregelatinized starch through an 80-mesh sieve; mix them evenly with the pulverized Spirulina extract, add water to make soft powder, granulate, and dry to a moisture content of less than 2%;

[0043] (2) After drying, add micronized silica gel and magnesium stearate to the granules, mix evenly, and then fill into empty capsules.

[0044] In the above embodiments, the preparation method of Dendrobium extract is as follows:

[0045] Take dried whole Dendrobium officinale, cut it into small sections, add 10-20 times its weight of deionized water and soak it at 80-90℃ for 3 times, 2 hours each time. After concentrating the extract, add an equal volume of anhydrous ethanol, centrifuge at 5000-8000 rpm for 15 minutes to separate the precipitate, add deionized water to dissolve it, centrifuge again, and freeze-dry the supernatant under vacuum to obtain Dendrobium officinale extract.

[0046] The preparation method of the Febuxostat capsule filler and spirulina extract is as follows:

[0047] Take spirulina powder, pulverize it into ultrafine powder, add 3-4 times the weight of water to spirulina, heat to 80-100℃ and soak for 8-10 hours, centrifuge at 5000-8000 rpm for 15 minutes to remove the precipitate, add an equal volume of anhydrous ethanol to the supernatant, stir thoroughly, and centrifuge again; take the precipitate, dissolve it in water, add 1 / 2 volume of anhydrous ethanol to the aqueous solution, stir thoroughly, centrifuge, and freeze-dry the precipitate to obtain spirulina extract.

[0048] The present invention describes the study on the uniformity of febuxostat content.

[0049] (1) Content uniformity test

[0050] Febuxostat capsules prepared according to the three embodiments of this invention were used as experimental groups. The control groups followed the formulation of Example 2, with control group 1 omitting spirulina extract, control group 2 omitting dendrobium extract, and control group 3 omitting alginate and magnesium stearate. After preparing febuxostat capsules according to the method of Example 2, the content uniformity was tested according to the method described in the 2020 edition of the Pharmacopoeia, Part IV, and the A+2.2S value of each treatment group capsule was calculated. If A+2.2S ≤ 15.0, the content uniformity of the capsules meets the requirements.

[0051] Table 1. Results of content uniformity test (%) of febuxostat capsules prepared by different methods

[0052] Processing group A+2.2S Example 1 6.5 Example 2 2.9 Example 3 4.1 Control group 1 13.5 Control group 2 11.8 Control group 3 18.6

[0053] As shown in Table 1, the A+2.2S value of control group 3 is higher than 15.0, which does not meet the requirements for capsules. Although the A+2.2S values ​​of control groups 1 and 2 meet the requirements for capsules, they are still higher than the A+2.2S values ​​of febuxostat capsules prepared in the three embodiments of this invention. Therefore, the febuxostat capsules described in the embodiments of this invention have significantly improved packaging uniformity and the drug content uniformity is significantly higher than that of the three control groups.

[0054] (2) Stability testing

[0055] Febuxostat capsules were prepared according to the methods described in Examples 1-3 and Control Groups 1-2, and packaged in aluminum-plastic packaging according to commercial standards. The capsules were stored for 6 months at a temperature of 40℃±2℃ and RH of 75±5%. Samples were taken at the end of months 0, 1, 2, 3, and 6 for content determination to compare the changes in the content of active ingredients in febuxostat capsules prepared by different methods.

[0056] Table 2. Determination of changes in the content of active ingredients in febuxostat capsules prepared by different methods (%)

[0057] October January February March June Example 1 98.03 99.75 98.99 100.42 99.10 Example 2 100.21 98.46 99.68 99.06 98.62 Example 3 99.37 100.05 98.47 100.55 99.73 Control group 1 99.42 98.79 99.65 98.43 90.64 Control group 2 101.33 99.56 100.18 99.15 93.11

[0058] As shown in Table 2, the active ingredient content of the febuxostat capsules in all three embodiments of the present invention remained relatively stable through accelerated stability testing. In contrast, although the active ingredient content in the two control groups remained constant for the first three months, it decreased to varying degrees by the sixth month, indicating that the febuxostat capsules of the present invention exhibit higher stability than the two control groups.

[0059] The specific embodiments of the present invention have been described in detail above, but they are merely examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions to the present invention are also within the scope of the present invention. Therefore, all equivalent transformations and modifications made without departing from the spirit and scope of the present invention should be covered within the scope of the present invention.

Claims

1. A febuxostat capsule filler, characterized in that, It is composed of the following components in parts by weight: febuxostat 10-50 parts, Dendrobium extract 10-20 parts, Spirulina extract 20-30 parts, micronized silica gel 5-15 parts, alginic acid 0.1-1 parts, mannitol 1-5 parts, citric acid 5-20 parts, pregelatinized starch 30-80 parts and magnesium stearate 0.5-3 parts; The preparation method of the Dendrobium extract is as follows: Take dried Dendrobium officinale whole herb, cut it into small sections, add 10-20 times the weight of the herb in deionized water, soak and extract three times at 80-90℃ for 2 hours each time. After the extract is concentrated, add anhydrous ethanol, centrifuge to separate the precipitate, add deionized water to dissolve, centrifuge again, and freeze-dry the supernatant under vacuum to obtain Dendrobium officinale extract. The preparation method of the spirulina extract is as follows: Take spirulina powder, pulverize it into ultrafine powder, add 3-4 times the weight of water to spirulina, heat to 80-100℃ and soak for 8-10 hours, centrifuge to remove the precipitate, add an equal volume of anhydrous ethanol to the supernatant, stir thoroughly and centrifuge; take the precipitate, dissolve it in water, add 1 / 2 volume of anhydrous ethanol to the aqueous solution, stir thoroughly and centrifuge, and dry the resulting precipitate to obtain spirulina extract.

2. The febuxostat capsule filler as described in claim 1, characterized in that, The Febuxostat capsule filler is composed of the following components in parts by weight: 30 parts febuxostat, 15 parts Dendrobium extract, 25 parts Spirulina extract, 10 parts micronized silica gel, 0.5 parts alginic acid, 3 parts mannitol, 15 parts citric acid, 50 parts pregelatinized starch, and 2.5 parts magnesium stearate.

3. The febuxostat capsule filler as described in claim 1, characterized in that, Centrifuge at 5000-8000 rpm for 15 minutes.

4. The use of a febuxostat capsule filler as described in any one of claims 1-3 in the preparation of febuxostat capsules.

5. A febuxostat capsule, characterized in that: It includes an empty capsule and a filler filling the empty capsule; the filler is the febuxostat capsule filler as described in any one of claims 1-3.

6. The method for preparing febuxostat capsules as described in claim 5, characterized in that, Includes the following steps: (1) Take Dendrobium extract and Spirulina extract separately and pulverize them into ultrafine powder; pulverize alginic acid, mannitol, citric acid and pregelatinized starch through a 60-80 mesh sieve; mix them evenly with the pulverized Spirulina extract, add water to make soft powder, granulate and dry; (2) After drying, add micronized silica gel and magnesium stearate to the granules, mix evenly, and then fill into empty capsules.

7. The method for preparing febuxostat capsules as described in claim 6, characterized in that, Both the Dendrobium extract and Spirulina extract were pulverized to a particle size of less than or equal to 30 μm.

8. The method for preparing febuxostat capsules as described in claim 6, characterized in that, In step (2), the particles are dried until the moisture content is less than 2%.

Citation Information

Patent Citations

  • Febuxostat capsule drug combination and preparation method thereof

    CN102000040A

  • Method for producing spirulina polysaccharide by fresh spirulina

    CN102827303A

  • Dendrobium candidum polysaccharide and polygonatum polysaccharide composition and preparation method and application thereof

    CN108057039A